Kate Gurney

Suggest Changes
Learn More
BACKGROUND Exenatide twice daily is a first-in-class glucagon-like peptide receptor agonist approved for the treatment of type 2 diabetes. The objective of this analysis was to evaluate the safety(More)
  • 1